Nephrol Dial Transplant (2000) 15: 1207-1211
© 2000 European Renal Association-European Dialysis and Transplant Association
Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients
Department of Nephrology, Medizinische Klinik Innenstadt, Ludwig-Maximilians-Universität, Munich, Germany
Background. Chronic inflammatory disorders or infections represent a major cause of hyporesponsiveness to recombinant human erythropoietin (rHuEpo). To test the hypothesis that dialysate-related cytokine induction alters the response to rHuEpo, we conducted a prospective study with matched pairs of chronic haemodialysis patients. We compared the effect of two dialysis fluids, differing in their microbiological quality, on the rHuEpo therapy.
Methods. Thirty male patients with end-stage renal disease maintained on regular haemodialysis were assigned either to a group treated with conventional (potentially microbiologically contaminated) dialysate (group I) or to a group treated with online-produced ultrapure dialysate (group II). Randomization was stratified according to the maintenance dose of rHuEpo necessary to maintain a target haemoglobin level of 10–10.5 g/dl. Patients were followed for 12 months. Kt/V was calculated by the formula of Daugirdas. Haemoglobin levels were measured weekly and serum ferritin concentrations were determined at 6-week intervals. C-reactive protein (CRP) and interleukin-6 (IL-6) was measured by an ELISA at the start of the study and after 3, 6 and 12 months.
Results. In group I, continuous use of bicarbonate dialysate did not change the rHuEpo dosage given to achieve the target haemoglobin level and was associated with elevated surrogate markers (CRP, IL-6) of cytokine-induced inflammation. The switch from conventional to online-produced ultrapure dialysate in group II resulted in a lower bacterial contamination with a significant decrease of CRP and IL-6 blood levels. It was accompanied by a significant and sustained reduction of the rHuEpo dosage, which was required to correct the anaemia. Using multiple regression analysis, IL-6 levels are shown to have a strong predictive value for rHuEpo dosage in both groups.
Conclusions. Our data demonstrate that dialysate-related factors such as low bacterial contamination can induce the activation of monocytes, resulting in elevated serum levels of IL-6. Dialysate-related cytokine induction might diminish erythropoiesis. The use of pyrogen free ultrapure dialysate resulted in a better response to rHuEpo. Not only would it save money, but it would also help to maintain an optimal haemoglobin level without further increase in rHuEpo dosage.
Keywords: biocompatibility; erythropoietin; interleukin-6; renal anaemia; ultrapure dialysate
Correspondence and offprint requests to: Professor Dr H. Schiffl, Medizinische Klinik der LMU, Ziemssenstr. 1, D-80336 München, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Glorieux, E. Schepers, R. Schindler, H.-D. Lemke, F. Verbeke, A. Dhondt, N. Lameire, and R. Vanholder A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test Nephrol. Dial. Transplant., February 1, 2009; 24(2): 548 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. de Francisco, P. Stenvinkel, and S. Vaulont Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus, January 1, 2009; 2(suppl_1): i18 - i26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Lamas, M. Alonso, F. Sastre, G. Garcia-Trio, J. Saavedra, and L. Palomares Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2851 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Regidor, J. D. Kopple, C. P. Kovesdy, R. D. Kilpatrick, C. J. McAllister, J. Aronovitz, S. Greenland, and K. Kalantar-Zadeh Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1181 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Panichi, G. Manca-Rizza, S. Paoletti, D. Taccola, C. Consani, C. Filippi, E. Mantuano, A. Sidoti, G. Grazi, A. Antonelli, et al. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs online haemodiafiltration: a cross-over randomized multicentre trial Nephrol. Dial. Transplant., March 1, 2006; 21(3): 756 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Ward Protein-Leaking Membranes for Hemodialysis: A New Class of Membranes in Search of an Application? J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2421 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Collins, J. Liu, and J. P. Ebben Dialyser reuse-associated mortality and hospitalization risk in incident Medicare haemodialysis patients, 1998-1999 Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1245 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Cooper, C. P. Breen, B. Vyas, J. Ochola, D. M. Kemeny, and I. C. Macdougall Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production Nephrol. Dial. Transplant., January 1, 2003; 18(1): 133 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, L. D. Vecchio, and S. Andrulli The modality of dialysis treatment: does it influence the response to erythropoietin treatment? Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1971 - 1974. [Full Text] [PDF]
|
|
|
|
|
|
A. Kato, M. Odamaki, T. Takita, M. Furuhashi, Y. Maruyama, and A. Hishida High blood soluble receptor p80 for tumour necrosis factor-{alpha} is associated with erythropoietin resistance in haemodialysis patients Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1838 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schiffl, S. M. Lang, D. Stratakis, and R. Fischer Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1863 - 1869. [Abstract] [Full Text] [PDF]
|
|